

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

13/a
mt
5/2/96

Application of : Kohn, *et al.*
Serial No. : 08/225,478
Filed: : April 8, 1994
For : Gene Therapy by Administration of Genetically Engineered CD34+ Cells Obtained from Cord Blood
Group : 1804
Examiner : Milne



Assistant Commissioner of Patents
Washington, D.C. 20231

AMENDMENT

Sir:

In response to the Office Action dated October 19, 1995, kindly amend the above-identified application as follows:

IN THE CLAIMS:

1. (Amended) A method of providing a therapeutic effect in a human patient, comprising:
administering [to said patient] autologous CD34+ cells obtained from cord blood
to said patient, said autologous CD34+ cells having been genetically engineered to include at least
one nucleic acid sequence encoding a therapeutic agent, [thereby] said autologous CD34+ cells
being administered in an amount effective to provide said patient with an effective amount of said
therapeutic agent by expression of said nucleic acid sequence in said patient.

A1
sent
B-1

6. (Amended) A method of treating a human patient suffering from severe combined immune deficiency resulting from adenosine deaminase deficiency, comprising:

administering [to said patient] autologous CD34+ cells obtained from cord blood
to said patient, said autologous CD34+ cells having been genetically engineered to include a
nucleic acid sequence encoding adenosine deaminase, said autologous CD34+ cells being
administered to said patient in an amount effective to treat said severe combined immune
deficiency resulting from adenosine deaminase deficiency in said patient by providing said patient

A2
sent
initial